Why Novavax Rose Even Though It Swung To A Loss

If you had been weighing Novavax on 1 January 2026, the choice was not just about a COVID-era vaccine story. For Novavax shareholders, the return from the start of the year was 57.9%, including dividends. That outcome makes the early-year debate more interesting than it first looked. If you were deciding then, how would you have balanced the promise of licensing deals against concerns over shrinking reported revenue and a much thinner margin profile?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

The easy part of this move is behind Novavax. Zero in on 33 high quality undervalued stocks for companies trading below our estimates.

The Two Novavax Stories Investors Had To Balance

The shares cost US$6.72 at the start of the period, and anyone weighing Novavax then had to choose between two sharply different stories built on the same set of uncertainties.

On the bullish side, the Narrative pointed to a Fair Value of US$12.5, 86% above the start price, based on a shift toward licensing, partnerships and a leaner model, even while revenue was assumed to decline 31.4% a year with profit margins at 16.0%.

The more cautious view saw Fair Value at US$6, 11% below the start price. It stressed the risk that heavier regulation, reliance on COVID and flu products, and assumed revenue falling 54.0% a year would leave Novavax needing a 72.6x future P/E to meet that case.

What The Evidence Did To The Novavax Argument

Novavax leaned into the licensing shift that bulls wanted, with a Pfizer Matrix-M deal, Sanofi payments and multiple transfer agreements pointing toward partner-led revenue. The hard figures pulled in the opposite direction. Quarterly revenue fell from US$239.24m in Q2 2025 to US$56.70m in Q2 2026, and net margin moved from 44.5% to a 94.2% loss. The evidence cut both ways.

The key assumption was that an asset-light model would offset weaker COVID demand with healthier earnings. For any similar story, track reported royalty and milestone income against total sales, and compare the resulting net margin to what the upbeat case implied.

What Novavax’s 58% Run-Up Expects From Here

Today Novavax trades at US$11.26, with this Narrative’s Fair Value sitting below that level. The focus is squarely on whether Matrix-M licensing can support partner-led revenue over time.

A buyer now is effectively assuming those licensing flows offset pressure on a narrow vaccine lineup. The question is how the selected Narrative’s execution and demand risks bear on that assumption.

"Heavy reliance on a limited vaccine portfolio and partners increases vulnerability to market saturation, operational risks, and diminishing revenue after short-term gains. Intensifying regulatory scrutiny and competition from larger players threaten margins, limit growth opportunities, and hinder Novavax's long-term profitability."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

How Could You Get There Earlier?

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 32% below our estimate - targets rising data centre power builds driven by GPU heavy AI workloads.
• Company 2 - 42% below our estimate - converts specialised scientific talent into litigation, safety and regulatory problem solving projects.
• Company 3 - 45% below our estimate - turns long data centre and industrial backlogs into modular and electrical buildouts.

Three companies from the same screener. Open the full list of 25 financially solid companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com